About US
Contact us
Position：Home > Phexcom News >
-
J&J undercuts Celgene's Pomalyst with $135K-per-year Darzalex priceJohnson & Johnson's ($JNJ) newmultiple myelomatreatment Darzalex (daratumumab) scored a speedy FDA approval, entering a market that's already crowded with last-ditch treatments. But the company is2015/11/18
-
AstraZeneca stokes Tagrisso's blockbuster hopes with $12,750-per-month stickerAstraZeneca ($AZN) unveiled its pricing plan for the new targeted lung cancer pill Tagrisso that won earlyFDAapproval Friday: $12,750 per month, or $153,000 for a full year of treatment. That's on par2015/11/18
-
Pharma faces 'challenging and prolonged' reforms in China, with pricing power at riskBig Pharma has already seen sales inChinaslow, thanks in part to stepped-up competition from local drugmakers. Healthcare reform there is also taking its toll. But Fitch Ratings says pharma's trouble2015/11/18
-
Valeant employees closely involved with Philidor operations: ReutersValeant's ad hoc committee isn't the only group probing Valeant's ties to specialty pharmacy Philidor. One new report says a small group of the company's employees was deeply involved in running the p2015/11/13
-
Roche cutting 1,200 jobs in major shift in producing drugsRoche ($RHHBY) will close four plants and lay off 1,200 people as it moves toward more biologics and new specialized small-molecule drugs that require less capacity. The drugmaker will take a $1.6 bil2015/11/13
-
Women sue Endo and Patheon after mixed-up contraceptives result in pregnanciesDrugmakers have paid out billions of dollars to patients who have claimed they have been harmed by drugs in one way or another. But what is a drugmaker's responsibility when a packaging problem result2015/11/13
-
Express Scripts cuts off Horizon-linked pharmacy in widening crackdownEarlier this month, in the wake of Valeant's ($VRX) canceled relationship with controversial specialty pharmacy Philidor, Express Scripts ($ESRX) said it would take a hard look at other specialty phar2015/11/12
-
Bondholders bail on Valeant amid cash flow concernsValeant ($VRX) may have terminated its relationship with controversial specialty pharmacy Philidor, but the move is going to cost it, with its dermatology and neurology businesses set to suffer. And c2015/11/12
-
Ready to rumble, Novartis? Roche targets melanoma-fighting combo market with new FDA nodWhen Novartis ($NVS) bought GlaxoSmithKline's ($GSK) oncology business, the newest products were a pair of targeted melanoma drugs,TafinlarandMekinist. The two meds had racked up trial data showing th2015/11/12
-
Scandal-plagued Valeant CEO focuses on damage controlIn the wake of its scrapped relationship with under-fire specialty pharmacy Philidor, Valeant ($VRX) is working to develop a new access program for dermatologists--something it thinks it can do within2015/11/11